These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 35201850)

  • 1. Plasma Cell-Free DNA Integrity Assessed by Automated Electrophoresis Predicts the Achievement of Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer.
    Cirmena G; Ferrando L; Ravera F; Garuti A; Dameri M; Gallo M; Barbero V; Ferrando F; Del Mastro L; Garlaschi A; Friedman D; Fregatti P; Ballestrero A; Zoppoli G
    JCO Precis Oncol; 2022 Feb; 6():e2100198. PubMed ID: 35201850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma cell-free DNA integrity: a potential biomarker to monitor the response of breast cancer to neoadjuvant chemotherapy.
    Wang W; Zhang W; Su L; Sang J; Wang S; Yao Y
    Transl Cancer Res; 2019 Aug; 8(4):1531-1539. PubMed ID: 35116896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma cell-free DNA integrity plus circulating tumor cells: a potential biomarker of no distant metastasis breast cancer.
    Wang W; Liang M; Ma G; Li L; Zhou W; Xia T; Xie H; Wang S
    Neoplasma; 2017; 64(4):611-618. PubMed ID: 28485169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
    Gampenrieder SP; Peer A; Weismann C; Meissnitzer M; Rinnerthaler G; Webhofer J; Westphal T; Riedmann M; Meissnitzer T; Egger H; Klaassen Federspiel F; Reitsamer R; Hauser-Kronberger C; Stering K; Hergan K; Mlineritsch B; Greil R
    Breast Cancer Res; 2019 Jan; 21(1):19. PubMed ID: 30704493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Case-Control Study by ddPCR of ALU 260/111 and LINE-1 266/97 Copy Number Ratio in Circulating Cell-Free DNA in Plasma Revealed LINE-1 266/97 as a Potential Biomarker for Early Breast Cancer Detection.
    Bortul M; Giudici F; Tierno D; Generali D; Scomersi S; Grassi G; Bottin C; Cappelletti MR; Zanconati F; Scaggiante B
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL.
    Hylton NM; Blume JD; Bernreuter WK; Pisano ED; Rosen MA; Morris EA; Weatherall PT; Lehman CD; Newstead GM; Polin S; Marques HS; Esserman LJ; Schnall MD;
    Radiology; 2012 Jun; 263(3):663-72. PubMed ID: 22623692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diffusion-weighted MRI for predicting pathologic response to neoadjuvant chemotherapy in breast cancer: evaluation with mono-, bi-, and stretched-exponential models.
    Suo S; Yin Y; Geng X; Zhang D; Hua J; Cheng F; Chen J; Zhuang Z; Cao M; Xu J
    J Transl Med; 2021 Jun; 19(1):236. PubMed ID: 34078388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ki-67 labeling index as a predictor of response to neoadjuvant chemotherapy in breast cancer.
    Jain P; Doval DC; Batra U; Goyal P; Bothra SJ; Agarwal C; Choudhary DK; Yadav A; Koyalla VPB; Sharma M; Dash P; Talwar V
    Jpn J Clin Oncol; 2019 Apr; 49(4):329-338. PubMed ID: 30753543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene Expression-Based Prediction of Neoadjuvant Chemotherapy Response in Early Breast Cancer: Results of the Prospective Multicenter EXPRESSION Trial.
    Edlund K; Madjar K; Lebrecht A; Aktas B; Pilch H; Hoffmann G; Hofmann M; Kolberg HC; Boehm D; Battista M; Seehase M; Stewen K; Gebhard S; Cadenas C; Marchan R; Brenner W; Hasenburg A; Koelbl H; Solbach C; Gehrmann M; Tanner B; Weber KE; Loibl S; Sachinidis A; Rahnenführer J; Schmidt M; Hengstler JG
    Clin Cancer Res; 2021 Apr; 27(8):2148-2158. PubMed ID: 33542080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of shear-wave elastography versus dynamic optical breast imaging for predicting the pathological response to neoadjuvant chemotherapy in breast cancer.
    Zhang J; Tan X; Zhang X; Kang Y; Li J; Ren W; Ma Y
    Eur J Radiol; 2020 Aug; 129():109098. PubMed ID: 32559591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer.
    Cheng J; Holland-Letz T; Wallwiener M; Surowy H; Cuk K; Schott S; Trumpp A; Pantel K; Sohn C; Schneeweiss A; Burwinkel B
    Breast Cancer Res Treat; 2018 May; 169(1):69-82. PubMed ID: 29340881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigating the prediction value of multiparametric magnetic resonance imaging at 3 T in response to neoadjuvant chemotherapy in breast cancer.
    Minarikova L; Bogner W; Pinker K; Valkovič L; Zaric O; Bago-Horvath Z; Bartsch R; Helbich TH; Trattnig S; Gruber S
    Eur Radiol; 2017 May; 27(5):1901-1911. PubMed ID: 27651141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathological complete response in invasive breast cancer treated by skin sparing mastectomy and immediate reconstruction following neoadjuvant chemotherapy and radiation therapy: Comparison between immunohistochemical subtypes.
    Barrou J; Bannier M; Cohen M; Lambaudie E; Gonçalves A; Bertrand P; Buttarelli M; Opinel P; Sterkers N; Tallet A; Zinzindohoué C; Houvenaeghel G
    Breast; 2017 Apr; 32():37-43. PubMed ID: 28033508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of pathological complete response in breast cancer patients during neoadjuvant chemotherapy: Is shear wave elastography a useful tool in clinical routine?
    Maier AM; Heil J; Harcos A; Sinn HP; Rauch G; Uhlmann L; Gomez C; Stieber A; Funk A; Barr RG; Hennigs A; Riedel F; Schäfgen B; Hug S; Marmé F; Sohn C; Golatta M
    Eur J Radiol; 2020 Jul; 128():109025. PubMed ID: 32371182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Texture Analysis with 3.0-T MRI for Association of Response to Neoadjuvant Chemotherapy in Breast Cancer.
    Eun NL; Kang D; Son EJ; Park JS; Youk JH; Kim JA; Gweon HM
    Radiology; 2020 Jan; 294(1):31-41. PubMed ID: 31769740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of MGMT, hMLH1, hMSH2 and BRCA1 protein expression for pathological complete response to neoadjuvant chemotherapy in basal-like breast cancer patients.
    Nakai K; Mitomi H; Alkam Y; Arakawa A; Yao T; Tokuda E; Saito M; Kasumi F
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):923-30. PubMed ID: 22083523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultrasound-based prediction of pathologic response to neoadjuvant chemotherapy in breast cancer patients.
    Baumgartner A; Tausch C; Hosch S; Papassotiropoulos B; Varga Z; Rageth C; Baege A
    Breast; 2018 Jun; 39():19-23. PubMed ID: 29518677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the influencing factors of the pathologic complete response in estrogen receptor-positive, HER2-negative breast cancer after neoadjuvant chemotherapy: a retrospective study.
    Tang L; Shu X; Tu G
    World J Surg Oncol; 2022 Jan; 20(1):27. PubMed ID: 35093083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alter circulating cell-free DNA variables in plasma of ovarian cancer patients.
    Yu Z; Qin S; Wang H
    J Obstet Gynaecol Res; 2019 Nov; 45(11):2237-2242. PubMed ID: 31502389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Machine Learning With Multiparametric Magnetic Resonance Imaging of the Breast for Early Prediction of Response to Neoadjuvant Chemotherapy and Survival Outcomes in Breast Cancer Patients.
    Tahmassebi A; Wengert GJ; Helbich TH; Bago-Horvath Z; Alaei S; Bartsch R; Dubsky P; Baltzer P; Clauser P; Kapetas P; Morris EA; Meyer-Baese A; Pinker K
    Invest Radiol; 2019 Feb; 54(2):110-117. PubMed ID: 30358693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.